Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Imunon, Inc. (IMNN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq Capital Market issuer. Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies and DNA vaccine technologies, and its filings offer detailed insight into clinical progress, capital structure and listing status.
Current reports on Form 8-K are central for tracking material events. Imunon uses 8-Ks to furnish press releases on quarterly financial results, announce conference calls and webcasts, describe capital markets transactions such as at-the-market equity offerings and registered direct offerings, and report stockholder meeting outcomes. Other 8-Ks document amendments to the Restated Certificate of Incorporation, including increases in authorized common stock and the implementation of a one-for-fifteen reverse stock split, as well as Nasdaq notices regarding minimum bid price and stockholders’ equity requirements and the subsequent confirmation of regained compliance.
Through 8-K items, investors can also follow how Imunon structures its financing, such as prospectus supplements filed under existing shelf registration statements on Form S-3 and the use of sales agents for ATM programs. These filings clarify the legal framework for share issuances and warrant exercises that affect outstanding equity.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when reviewed alongside 8-Ks, provide broader context on clinical programs like IMNN-001 and IMNN-101, risk factors, and research and development spending, although these specific forms are not reproduced in the excerpts here. For insider activity, Form 4 filings would show transactions by directors and officers, complementing the governance information disclosed in proxy-related materials.
On Stock Titan, Imunon filings are updated in near real time from EDGAR, and AI-powered summaries can help explain complex sections of 10-Ks, 10-Qs and 8-Ks in plain language. This allows investors to quickly understand how corporate actions, listing compliance steps and financing decisions intersect with the company’s clinical-stage biotechnology strategy.
Imunon, Inc. reported that director Frederick J. Fritz received a stock option grant on January 2, 2026. The Form 4 shows a derivative award of a Stock Option (Right to Buy) covering 5,892 shares of Imunon common stock at an exercise price of $3.95 per share, which was the closing stock price on the grant date.
The option was granted for no cash payment and is held directly by Fritz, with 5,892 derivative securities beneficially owned after the transaction. According to the vesting terms, 1/2 vests on the grant date, 1/4 on the one-year anniversary, and 1/4 on the second anniversary, and the option expires on January 2, 2036.
Imunon, Inc. Chief Medical Officer Douglas Vincent Faller reported a new stock option grant for 12,667 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $3.95 per share, equal to the closing price of Imunon common stock on the grant date. The filing shows the options were acquired at a price of $0 as part of an equity award and are held directly.
The options vest over time: one-half of the grant vests on the grant date, one-quarter on the first anniversary, and the remaining one-quarter on the second anniversary of the grant date. The options are exercisable through January 2, 2036, providing the CMO with long-term equity-based incentives tied to Imunon’s share price performance.
Imunon, Inc. Executive Chairman Michael H. Tardugno received a grant of stock options for 43,821 shares on January 2, 2026. The options give him the right to buy Imunon common stock at an exercise price of $3.95 per share, which the disclosure notes was the closing price of the stock on the grant date.
The options were granted at no cash cost for the derivative security itself and expire on January 2, 2036. They vest over time, with one-half vesting on the grant date, one-quarter on the one-year anniversary of the grant, and the remaining one-quarter on the second anniversary. Following this grant, Tardugno beneficially owns 43,821 stock options directly.
Imunon, Inc. filed a Form S-8 to register an additional 133,333 shares of common stock for issuance under the Imunon, Inc. 2018 Stock Incentive Plan, as amended.
Shareholders approved the plan amendment on July 11, 2025 to increase the shares available by 133,333. The filing incorporates prior Imunon S-8 registrations by reference and includes customary exhibits such as legal opinions and auditor consents.
Imunon, Inc. reported Q3 2025 results and operational updates. The company posted a net loss of $3.43 million for the quarter and $10.27 million for the nine months ended September 30, 2025. Operating expenses fell to $3.48 million in Q3 (from $4.96 million a year ago) and to $10.39 million for the nine-month period (from $14.99 million), driven by lower research and development spending.
Cash and cash equivalents were $5.25 million as of September 30, 2025. Year to date, Imunon used $10.24 million in operating cash flows and raised $9.89 million via equity financings and warrant exercises. Management disclosed substantial doubt about the company’s ability to continue as a going concern. As of November 10, 2025, shares outstanding were 3,070,354.
The company effected a 15‑for‑1 reverse stock split on July 25, 2025, increased authorized common shares to 350,000,000 on July 11, and issued a 15% stock dividend on August 21. Clinically, positive Phase 2 OVATION 2 data support IMNN‑001 in advanced ovarian cancer, and the Phase 3 OVATION 3 trial began enrolling in July 2025 with four sites open as of quarter end.
Imunon, Inc. furnished an 8‑K stating it issued a press release reporting financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and, consistent with Item 2.02, the information is furnished and not deemed filed under the Exchange Act or Securities Act.
The company also referenced a conference call scheduled for November 13, 2025, announced on November 6, 2025, with a live webcast available at http://www.imunon.com.
Imunon, Inc. (IMNN) reporting person Stacy Lindborg, President & CEO and director, had 1,667 restricted shares vest on September 6, 2025, resulting in an acquisition of 1,667 common shares at $0 per share. After the vesting, Ms. Lindborg beneficially owned 3,584 shares directly and 234 shares indirectly through a 401(k) plan. The filing notes corporate equity adjustments: a 1-for-15 reverse stock split effective July 25, 2025, and a 15% stock dividend paid August 21, 2025, which adjusted previously reported share amounts. The Form 4 was signed by an attorney-in-fact on September 9, 2025.
Imunon, Inc. reports that it has received written notice from a Nasdaq Hearings Panel that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
This confirms that Imunon’s common stock, trading under the symbol IMNN, currently meets this key Nasdaq standard and removes the immediate listing risk tied specifically to its share price, as long as the company continues to satisfy applicable Nasdaq rules.
Imunon, Inc. received a Schedule 13G/A reporting that three related reporting persons — Ayrton Capital LLC, Alto Opportunity Master Fund, SPC (Segregated Master Portfolio B) and individual Waqas Khatri — each beneficially own 2,000 shares of the issuer's common stock that are issuable on the exercise of certain warrants and conversion of certain convertible notes. The filing states these holdings represent 0.01% each based on 17,541,732 shares outstanding cited in the issuer's registration statement prior to a July 2025 reverse stock split.
The filing notes the warrants are subject to a 9.99% beneficial ownership blocker and includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC disclose beneficial ownership in Imunon, Inc. The filing shows each may be deemed to beneficially own 1,067,196 shares of common stock, representing 4.99% of the class. That figure is calculated using the issuer's reported outstanding shares of 20,319,511 plus 1,067,196 shares issuable upon exercise of an Intracoastal warrant.
The report states sole voting and dispositive power are 0 and shared voting and dispositive power are 1,067,196. It also discloses an additional 1,155,028 warrant shares are excluded because the warrant is not currently exercisable pending stockholder approval and includes a blocker limiting exercise above 4.99%. Without that blocker and if currently exercisable, the filing notes each reporting person could be deemed to own 2,222,224 shares.